Pfizer Taps Beer Skills to Enter $14 Billion Insulin Market Biocon Ltd. founder Kiran Mazumdar- Shaw learned the intricacies of enzymes while studying how to make beer. Now Pfizer Inc., the world’s largest drugmaker, is tapping that knowledge to revive its insulin business. [Bloomberg] JDRF: Accelerating Early Stage Programs for Diabetes The Juvenile Diabetes Research Foundation (JDRF) has begun to work more closely with industry to ensure that promising discoveries make their way through from early stage research to the patient. [Partnering News] Sirona Biochem Announces Private Placement of CDN$2,500,000 Sirona Biochem Corporation, a biotechnology company developing therapeutics for diabetes and obesity, announced that it is proposing to complete a private placement of 10,000,000 units of the Company at a price of $0.25 per unit for total proceeds of CDN$2,500,000. [Sirona Biochem Corporation Press Release] McKesson Foundation Awards $1.3 Million to Researchers Studying How Mobile Technology Can Help Patients Manage Diabetes The McKesson Foundation announced the six recipients of $1.3 million in research grants as part of its Mobilizing for Healthsm initiative to improve the health of underserved populations with chronic diseases through the use of mobile-phone technology. [McKesson Foundation Press Release] LCT’s World-Leading Encapsulating Technology Granted Vital Australian Patent Living Cell Technologies (LCT) Limited a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been granted a patent by the Australian Patent Office for IMMUPEL™, LCT’s industry-leading technology for encapsulating living cells prior to transplantation. [Living Cell Technologies Limited Press Release] Infinity Initiates Phase II Portion of Trial of IPI-926 in Pancreatic Cancer Infinity Pharmaceuticals, Inc. announced the initiation of the randomized Phase II portion of the trial of IPI-926 in combination with gemcitabine (also known as Gemzar®) in patients with previously untreated, metastatic, pancreatic cancer. [Infinity Pharmaceuticals, Inc. Press Release] Furiex Confirms Takeda Receives Approval of Additional NESINA® Combination Therapies with Sulfonylurea and Biguanide for Type 2 Diabetes in Japan Furiex Pharmaceuticals, Inc. confirmed that Takeda Pharmaceutical Company Limited’s applications for two additional indications for “NESINA®” (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare. [Furiex Pharmaceuticals, Inc. Press Release] LCT Appoints Investment Banker to Board of Directors Living Cell Technologies Limited (LCT) announced the appointment of Roy Austin to the Board of Directors. [Living Cell Technologies Limited Press Release] |